Loading...

Thyrocare Technologies

NSEI:THYROCARE
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
THYROCARE
NSEI
₹30B
Market Cap
  1. Home
  2. IN
  3. Healthcare
Company description

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. The last earnings update was 13 days ago. More info.


Add to Portfolio Compare Print
THYROCARE Share Price and Events
7 Day Returns
12.4%
NSEI:THYROCARE
1%
IN Healthcare
-0.1%
IN Market
1 Year Returns
-9.1%
NSEI:THYROCARE
-13.9%
IN Healthcare
-7.5%
IN Market
THYROCARE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Thyrocare Technologies (THYROCARE) 12.4% 3.2% 4% -9.1% - -
IN Healthcare 1% -4.8% -2.3% -13.9% -14.3% 34.9%
IN Market -0.1% -3.2% -1.7% -7.5% 46.6% 79.6%
1 Year Return vs Industry and Market
  • THYROCARE outperformed the Healthcare industry which returned -13.9% over the past year.
  • THYROCARE underperformed the Market in India which returned -7.5% over the past year.
Price Volatility
THYROCARE
Industry
5yr Volatility vs Market

THYROCARE Value

 Is Thyrocare Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Thyrocare Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our calculation method for this is changing soon.

Below are the data sources, inputs and calculation used to determine the intrinsic value for Thyrocare Technologies.

NSEI:THYROCARE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 13.5%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NSEI:THYROCARE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 7.5%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.463 (1 + (1- 35%) (0.33%))
0.464
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.8 * 7.45%)
13.51%

Discounted Cash Flow Calculation for NSEI:THYROCARE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Thyrocare Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

NSEI:THYROCARE DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (INR, Millions) 738.31 872.28 1,029.29 1,204.27 1,396.95
Source Est @ 18.15% Est @ 18.15% Est @ 18%, capped from 18.15% Est @ 17%, capped from 18.15% Est @ 16%, capped from 18.15%
Present Value
Discounted (@ 13.51%)
650.44 677.00 703.78 725.41 741.33
Present value of next 5 years cash flows ₹3,497.95
NSEI:THYROCARE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= ₹1,396.95 × (1 + 7.55%) ÷ (13.51% – 7.55%)
₹25,208.37
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= ₹25,208.37 ÷ (1 + 13.51%)5
₹13,377.47
NSEI:THYROCARE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= ₹3,497.95 + ₹13,377.47
₹16,875.42
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹16,875.42 / 52.80
₹318.27
NSEI:THYROCARE Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in NSEI:THYROCARE represents 0.99578x of BSE:539871
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99578x
Value per Share
(Listing Adjusted, INR)
= Value per Share (INR) x Listing Adjustment Factor
= ₹ 319.62 x 0.99578
₹318.27
Value per share (INR) From above. ₹318.27
Current discount Discount to share price of ₹566.20
= -1 x (₹566.20 - ₹318.27) / ₹318.27
-77.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Thyrocare Technologies is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Thyrocare Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Thyrocare Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:THYROCARE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in INR ₹17.50
BSE:539871 Share Price ** BSE (2019-02-21) in INR ₹568.6
India Healthcare Industry PE Ratio Median Figure of 23 Publicly-Listed Healthcare Companies 24.61x
India Market PE Ratio Median Figure of 2,709 Publicly-Listed Companies 15.3x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Thyrocare Technologies.

NSEI:THYROCARE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:539871 Share Price ÷ EPS (both in INR)

= 568.6 ÷ 17.50

32.49x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Thyrocare Technologies is overvalued based on earnings compared to the IN Healthcare industry average.
  • Thyrocare Technologies is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does Thyrocare Technologies's expected growth come at a high price?
Raw Data
NSEI:THYROCARE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 32.49x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
Asia Healthcare Industry PEG Ratio Median Figure of 13 Publicly-Listed Healthcare Companies 1.88x
India Market PEG Ratio Median Figure of 604 Publicly-Listed Companies 1.15x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Thyrocare Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Thyrocare Technologies's assets?
Raw Data
NSEI:THYROCARE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in INR ₹83.98
BSE:539871 Share Price * BSE (2019-02-21) in INR ₹568.6
India Healthcare Industry PB Ratio Median Figure of 32 Publicly-Listed Healthcare Companies 2.01x
India Market PB Ratio Median Figure of 3,588 Publicly-Listed Companies 1.04x
NSEI:THYROCARE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:539871 Share Price ÷ Book Value per Share (both in INR)

= 568.6 ÷ 83.98

6.77x

* Primary Listing of Thyrocare Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Thyrocare Technologies is overvalued based on assets compared to the IN Healthcare industry average.
X
Value checks
We assess Thyrocare Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Thyrocare Technologies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

THYROCARE Future Performance

 How is Thyrocare Technologies expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.4%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is Thyrocare Technologies expected to grow at an attractive rate?
  • Thyrocare Technologies's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Thyrocare Technologies's earnings growth is expected to exceed the India market average.
  • Thyrocare Technologies's revenue growth is expected to exceed the India market average.
Annual Growth Rates Comparison
Raw Data
NSEI:THYROCARE Future Growth Rates Data Sources
Data Point Source Value (per year)
NSEI:THYROCARE Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 21.4%
NSEI:THYROCARE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 15.1%
India Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 42.9%
India Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 13.2%
India Market Earnings Growth Rate Market Cap Weighted Average 18.5%
India Market Revenue Growth Rate Market Cap Weighted Average 11.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:THYROCARE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:THYROCARE Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-03-31 5,667 1
2020-03-31 4,579 1
2019-03-31 4,234 1,143 2
NSEI:THYROCARE Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2018-12-31 3,946 939
2018-09-30 3,822 953
2018-06-30 3,663 947
2018-03-31 3,569 1,070 933
2017-12-31 3,493 1,117
2017-09-30 3,359 994
2017-06-30 3,258 759
2017-03-31 3,045 896 428
2016-12-31 2,843 659
2016-09-30 2,699 601
2016-06-30 2,535 564
2016-03-31 2,411 678 518

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Thyrocare Technologies's earnings are expected to grow significantly at over 20% yearly.
  • Thyrocare Technologies's revenue is expected to grow by 15.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:THYROCARE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Thyrocare Technologies Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:THYROCARE Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-03-31 28.82 28.82 28.82 1.00
2020-03-31 23.15 23.15 23.15 1.00
2019-03-31 19.65 21.30 18.00 2.00
NSEI:THYROCARE Past Financials Data
Date (Data in INR Millions) EPS *
2018-12-31 17.50
2018-09-30 17.72
2018-06-30 17.61
2018-03-31 17.36
2017-12-31 20.82
2017-09-30 18.49
2017-06-30 14.13
2017-03-31 8.00
2016-12-31 12.27
2016-09-30 11.32
2016-06-30 10.79
2016-03-31 10.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Thyrocare Technologies is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Thyrocare Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Thyrocare Technologies has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

THYROCARE Past Performance

  How has Thyrocare Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Thyrocare Technologies's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Thyrocare Technologies's year on year earnings growth rate has been positive over the past 5 years.
  • Thyrocare Technologies's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Thyrocare Technologies's 1-year earnings growth is negative, it can't be compared to the IN Healthcare industry average.
Earnings and Revenue History
Thyrocare Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Thyrocare Technologies Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:THYROCARE Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3,945.91 939.45 237.03
2018-09-30 3,821.61 952.65 237.03
2018-06-30 3,663.21 946.65 237.03
2018-03-31 3,569.31 932.75 237.03
2017-12-31 3,493.42 1,116.79 124.94
2017-09-30 3,358.52 993.93 124.94
2017-06-30 3,258.17 759.06
2017-03-31 3,045.34 428.45 220.28
2016-12-31 2,843.24 659.46 120.08
2016-09-30 2,699.18 601.03 120.08
2016-06-30 2,534.69 564.38 120.08
2016-03-31 2,411.03 518.00 120.08
2015-03-31 1,835.41 452.17 69.09
2014-03-31 1,502.30 461.56 56.54
2013-03-31 1,342.61 568.19 47.61
2012-03-31 1,090.76 349.43 59.28

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Thyrocare Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Thyrocare Technologies used its assets more efficiently than the IN Healthcare industry average last year based on Return on Assets.
  • Thyrocare Technologies has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Thyrocare Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Thyrocare Technologies has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

THYROCARE Health

 How is Thyrocare Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Thyrocare Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Thyrocare Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Thyrocare Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Thyrocare Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 15.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Thyrocare Technologies Company Filings, last reported 1 month ago.

NSEI:THYROCARE Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4,513.50 99.30 882.40
2018-09-30 4,513.50 99.30 882.40
2018-06-30 4,432.90 106.24 1,119.55
2018-03-31 4,432.90 106.24 1,119.55
2017-12-31 4,258.29 98.44 1,367.24
2017-09-30 4,258.29 98.44 1,367.24
2017-06-30 4,067.83 0.00 1,130.70
2017-03-31 4,078.08 72.50 1,159.53
2016-12-31 4,033.42 0.00 1,179.52
2016-09-30 4,033.42 0.00 1,179.52
2016-06-30 3,656.10 0.00 1,019.26
2016-03-31 3,656.10 0.00 1,019.26
2015-03-31 3,123.83 0.00 893.76
2014-03-31 2,062.63 250.00 1,132.94
2013-03-31 1,601.07 250.00 771.33
2012-03-31 1,024.76 250.00 590.31
  • Thyrocare Technologies's level of debt (2.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (12.8% vs 2.2% today).
  • Debt is well covered by operating cash flow (1077.9%, greater than 20% of total debt).
  • Thyrocare Technologies earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Thyrocare Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Thyrocare Technologies has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

THYROCARE Dividends

 What is Thyrocare Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.76%
Current annual income from Thyrocare Technologies dividends.
If you bought ₹2,000 of Thyrocare Technologies shares you are expected to receive ₹35 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Thyrocare Technologies's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.56%).
  • Thyrocare Technologies's dividend is below the markets top 25% of dividend payers in India (2.08%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:THYROCARE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
India Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.7%
India Market Average Dividend Yield Market Cap Weighted Average of 1397 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.6%
India Top 25% Dividend Yield 75th Percentile 2.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:THYROCARE Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2021-03-31
2020-03-31
2019-03-31
NSEI:THYROCARE Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2018-07-23 10.000 1.735
2018-02-05 10.000 1.639
2017-08-17 10.000 1.467
2017-06-12 10.000 1.384
2017-05-09 10.000 1.397
2017-01-30 10.000 1.403
2016-06-13 2.500 0.405
2016-05-09 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Thyrocare Technologies has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Thyrocare Technologies only paid a dividend in the past 3 years.
Current Payout to shareholders
What portion of Thyrocare Technologies's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.5x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Thyrocare Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Thyrocare Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Thyrocare Technologies has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

THYROCARE Management

 What is the CEO of Thyrocare Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
A. Velumani
COMPENSATION ₹12
AGE 59
CEO Bio

Dr. A. Velumani, Ph.D., is the Founder of Nueclear Healthcare Ltd. in 2011 and serves as its Chief Executive Officer and also has been Managing Director since April 1, 2014 and has been its Director since September 27, 2013. Dr. Velumani is the Founder, Managing Director and Chief Executive Officer of Thyrocare Technologies Limited. Mr. Velumani served as Chief Executive Officer of Thyrocare Laboratories, Ltd. until January 17, 2011 and Eins Edutech Ltd. until January 15, 2011. Dr. Velumani is an ex Scientist from BARC. Dr. Velumani serves as a Director of Nueclear Healthcare Ltd. He is a graduate in science from the University of Madras, a post graduate in science from the University of Bombay and a Doctorate in Philosophy with science from the University of Bombay.

CEO Compensation
  • A.'s compensation has been consistent with company performance over the past year.
  • A.'s remuneration is lower than average for companies of similar size in India.
Management Team

A. Velumani

TITLE
Chairman
COMPENSATION
₹12
AGE
59

A. Sundararaju

TITLE
CFO & Executive Director
COMPENSATION
₹6M
AGE
60
TENURE
3.9 yrs

Ramjee Dorai

TITLE
Head of Secretarial & Legal
COMPENSATION
₹2M
AGE
71
TENURE
3.2 yrs

Caesar Sengupta

TITLE
Vice President of Operations
COMPENSATION
₹4M
AGE
44

M. Chandrasekhar

TITLE
General Manager of Infrastructure
COMPENSATION
₹3M
AGE
34

Sachin Salvi

TITLE
General Manager of Finance
COMPENSATION
₹2M
AGE
37

M. Santhosh

TITLE
General Manager of Business Development
COMPENSATION
₹2M
AGE
36

S. Krishnakumar

TITLE
Deputy General Manager of Laboratory
COMPENSATION
₹1M
AGE
47

Rajkumar Kushawaha

TITLE
Deputy General Manager of Laboratory
COMPENSATION
₹588K
AGE
38
Board of Directors Tenure

Average tenure and age of the Thyrocare Technologies board of directors in years:

4.4
Average Tenure
58
Average Age
  • The tenure for the Thyrocare Technologies board of directors is about average.
Board of Directors

A. Sundararaju

TITLE
CFO & Executive Director
COMPENSATION
₹6M
AGE
60
TENURE
19.1 yrs

Gopalkrishna Hegde

TITLE
Independent Director
COMPENSATION
₹120K
AGE
58
TENURE
4.5 yrs

A. Velumani

TITLE
Chairman
COMPENSATION
₹12
AGE
59

Amruta Velumani

TITLE
Non-Executive Director
COMPENSATION
₹16M
AGE
27
TENURE
3 yrs

Vishwas Kulkarni

TITLE
Independent Director
COMPENSATION
₹110K
AGE
56
TENURE
4.5 yrs

N. Palanisamy

TITLE
Independent Director
COMPENSATION
₹50K
AGE
69
TENURE
4.4 yrs

Neetin Desai

TITLE
Independent Director
COMPENSATION
₹30K
AGE
48
TENURE
4.4 yrs

Indumati Gopinathan

TITLE
Non-Executive Non-Independent Director
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Thyrocare Technologies insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
16. Feb 19 Buy A. Velumani Individual 14. Feb 19 15. Feb 19 148,172 ₹495.24 ₹73,286,368
15. Feb 19 Buy A. Velumani Individual 13. Feb 19 13. Feb 19 82,962 ₹498.85 ₹41,385,582
X
Management checks
We assess Thyrocare Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Thyrocare Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

THYROCARE News

Simply Wall St News

Interested In Thyrocare Technologies Limited (NSE:THYROCARE)? Here's How It Performed Recently

When Thyrocare Technologies Limited (NSE:THYROCARE) announced its most recent earnings (31 December 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … Did THYROCARE perform worse than its track record and industry. … Furthermore, this one-year growth rate has been lower than its average earnings growth rate over the past 5 years of 19%, indicating the rate at which THYROCARE is growing has slowed down

Simply Wall St -

Thyrocare Technologies Limited (NSE:THYROCARE): Commentary On Fundamentals

In the case of Thyrocare Technologies Limited (NSE:THYROCARE), there's. … is a company with great financial health as well as a. … For those interested in understanding where the figures come from and want to see the analysis,

Simply Wall St -

What Can We Make Of Thyrocare Technologies Limited’s (NSE:THYROCARE) High Return On Capital?

Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … What is Return On Capital Employed (ROCE)? … How Do You Calculate Return On Capital Employed

Simply Wall St -

Do You Know What Thyrocare Technologies Limited's (NSE:THYROCARE) P/E Ratio Means?

We'll show how you can use Thyrocare Technologies Limited's (NSE:THYROCARE) P/E ratio to inform your assessment of the investment opportunity. … How Do I Calculate Thyrocare Technologies's Price To Earnings Ratio … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

Want To Invest In Thyrocare Technologies Limited (NSE:THYROCARE) Today? Read This First

Thyrocare Technologies Limited (NSE:THYROCARE) is considered a high-growth stock, but its last closing price of ₹555 left some investors wondering if this high future earnings potential can be rationalized by its current price tag. … View our latest analysis for Thyrocare Technologies? … Analysts are predicting good growth prospects for Thyrocare Technologies over the next couple of years

Simply Wall St -

July Insights Into Healthcare Stocks: Thyrocare Technologies Limited (NSE:THYROCARE)

is a healthcare company operating in an industry, … which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of chronic diseases … A focus towards more collaborative and data-driven care models, which address behavioural and physical health of chronic illness or aging patients, may help improve patient outcomes and lowered costs.

Simply Wall St -

Does Thyrocare Technologies Limited's (NSE:THYROCARE) Past Performance Indicate A Stronger Future?

In this commentary, I will examine Thyrocare Technologies Limited's (NSE:THYROCARE) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, as well as how the rest of the healthcare industry performed. … Did THYROCARE's recent earnings growth beat the long-term trend and the industry. … THYROCARE's trailing twelve-month earnings (from 31 March 2018) of ₹932.75m has

Simply Wall St -

With An ROE Of 21.04%, Has Thyrocare Technologies Limited's (NSE:THYROCARE) Management Done Well?

and looking to gauge the potential return on investment in Thyrocare Technologies Limited (NSE:THYROCARE). … With an ROE of 21.04%, Thyrocare Technologies Limited (NSE:THYROCARE) outpaced its own industry which delivered a less exciting 8.83% over the past year. … If THYROCARE borrows debt to invest in its business, its profits will be higher.

Simply Wall St -

Thyrocare Technologies Limited (NSE:THYROCARE): A Fundamentally Attractive Investment

As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook. … In the case of Thyrocare Technologies Limited (NSE:THYROCARE), it

Simply Wall St -

Is Thyrocare Technologies Limited (NSE:THYROCARE) Expensive For A Reason? A Look At The Intrinsic Value

I am going to run you through how I calculated the intrinsic value of Thyrocare Technologies Limited (NSEI:THYROCARE) by taking the expected future cash flows and discounting them to their present value. … 5-year cash flow forecast 2018 2019 2020 2021 2022 Levered FCF (₹, Millions) ₹711.78 ₹774.33 ₹1,046.93 ₹1,710.50 ₹1,856.00 Source Analyst x4 Analyst x3 Analyst x4 Analyst x2 Analyst x2 Present Value Discounted @ 13.55% ₹626.86 ₹600.60 ₹715.15 ₹1,029.05 ₹983.37 Present Value of 5-year Cash Flow (PVCF)= ₹3,955 We now need to calculate the Terminal Value, which accounts for all the future cash flows after the five years. … Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = ₹1,856 × (1 + 7.7%) ÷ (13.5% – 7.7%) = ₹34,379 Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = ₹34,379 / ( 1 + 13.5%)5 = ₹18,215 The total value, or equity value, is then the sum of the present value of the cash flows, which in this case is ₹22,170.

Simply Wall St -

THYROCARE Company Info

Map
Description

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. The company operates through Pathology, Radiology, and Sale of Testing Equipment and Consumables segments. It conducts medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases, including thyroid disorders, growth disorders, metabolism disorders, auto-immunity, diabetes, anemia, cardiovascular disorders, infertility, and various infectious diseases. Its profiles of tests include 15 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also provides PET-CT scan imaging diagnostic services. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India.

Details
Name: Thyrocare Technologies Limited
THYROCARE
Exchange: NSEI
Founded: 1996
₹30,021,287,371
52,798,606
Website: http://www.thyrocare.com
Address: Thyrocare Technologies Limited
D/37-3, TTC Industrial Area,
MIDC Turbhe,
Navi Mumbai,
Maharashtra, 400703,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 539871 Equity Shares Mumbai Stock Exchange IN INR 09. May 2016
NSEI THYROCARE Equity Shares National Stock Exchange of India IN INR 09. May 2016
Number of employees
Current staff
Staff numbers
985
Thyrocare Technologies employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/22 13:05
End of day share price update: 2019/02/21 00:00
Last estimates confirmation: 2019/02/13
Last earnings filing: 2019/02/09
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.